There's a great new kind of cholesterol-lowering drug available, but few people are eligible to use it. The new PCSK9 inhibitors are a major step forward in cholesterol control. They work by increasing the removal of low-density lipoprotein (LDL) or “bad” cholesterol from the blood. They can reduce LDL by 60 percent, cutting the risk of major cardiac events considerably. But the drugs, like Repatha (evolocumab) and Praluent (alirocumab), cost much more than other cholesterol-lowering drugs — about $14,300 a year on average.
The cost means that heart patients need prior authorization by their health insurance companies to get a prescription, and there's the rub: over half of the patients who applied for approval to be prescribed the new LDL-lowering drugs were denied by their insurers.
“…[W]e were anticipating that there might be some reluctance by insurance companies to cover these medications. However, we were surprised by the very high rate of rejection [of permission for the prescriptions], even when prescribed to patients with known atherosclerotic cardiovascular disease, very high LDL levels and those who were intolerant of statins, for example,” Robert Yeh, the senior author of a new study that looked at prescribing trends for the drugs, said in a statement.
The lowest approval rates were from private insurance and the highest approval rates from Medicare.
The kind of insurance a person had was the most significant factor in whether he or she was approved. The lowest approval rates were from private insurance and the highest approval rates from Medicare.
“Whether or not we can agree on the cost-effectiveness of these drugs, I believe most would agree that one's access to medications should be driven primarily by the strength of the indications for the prescription as opposed to what drug plan you happen to carry,” said Yeh, director of the Smith Center for Outcomes Research in Cardiology at Beth Israel Deaconess Medical Center in Boston and an Associate Professor of Medicine at Harvard Medical School.
Cost was a disincentive even among patients who were approved for the drug. “Approximately 1 out of 3 patients who had their prescription approved did not purchase or receive the medication. Those patients who didn't purchase their medication had an out-of-pocket cost that was twice as high as those who did purchase it,” said Gregory Hess, the first author on the study and a senior fellow of Health Economics at University of Pennsylvania.
The study is published open access in the American Heart Association journal, Circulation.